Immunogenicity profile of a 3.75-μg hemagglutinin pandemic rH5N1 split virion AS03A-adjuvanted vaccine in elderly persons: a randomized trial

Stéphane Heijmans, Marc De Meulemeester, Paul Reynders, Didier Giet, Etienne Demanet, Pierre-Yves Devresse, Giancarlo Icardi, Mamadou Dramé, François Roman, Paul Gillard, Stéphane Heijmans, Marc De Meulemeester, Paul Reynders, Didier Giet, Etienne Demanet, Pierre-Yves Devresse, Giancarlo Icardi, Mamadou Dramé, François Roman, Paul Gillard

Abstract

Background: Elderly persons often experience a reduced immune response to influenza vaccination. We evaluated the usual dose of AS03(A)-adjuvanted H5N1 pandemic vaccine (3.75 μg hemagglutinin of A/Vietnam/1194/2004-like strain) compared with a double dose in an elderly population.

Methods: This phase 2, open-label study (NCT00397215; http://www.clinicaltrials.gov) randomized participants (age, ≥61 years) to receive, on days 0 and 21: (1) a single dose of AS03(A)-adjuvanted vaccine (n=152), (2) a single dose of nonadjuvanted vaccine (n=54), (3) a double dose of AS03(A)-adjuvanted vaccine (n=145), or (4) a double dose of nonadjuvanted vaccine (n=44). The primary end point was hemagglutination inhibition (HI) and neutralizing antibody response against vaccine antigen (according-to-protocol cohort).

Results: Day 42 geometric mean titers for HI antibodies were 126.8 and 237.3 for single and double doses of the AS03(A)-adjuvanted vaccine, respectively. Corresponding values for neutralizing antibodies were 447.3 and 595.8. Although the immune response was higher with the double dose, European Committee for Human Medicinal Products criteria for seroconversion and seroprotection rates were achieved in both AS03(A)-adjuvanted groups. Antigen-specific CD4 T cell responses were elicited. Immune response persistence at 6 months was high. Immune response in the non-adjuvanted groups was considerably less.

Conclusions: The AS03(A)-adjuvanted H5N1 vaccine can be administered elderly persons at the same dose and schedule as in younger adults.

© The Author 2011. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved.

Figures

Figure 1.
Figure 1.
Disposition of study participants. Vaccination groups are as follows: 1 × H5N1-AS, single dose of the AS03A-adjuvanted vaccine; 1 × H5N1, single dose of the nonadjuvanted vaccine; 2 × H5N1-AS, double dose of the AS03A-adjuvanted vaccine; 2 × H5N1, double dose of the nonadjuvanted vaccine. AE, adverse event; ATP, according-to-protocol; SAE, serious adverse event; TVC, total vaccinated cohort.
Figure 2.
Figure 2.
CD4 T cells specific for A/Vietnam/1194/2004 split-virus antigen, positive for ≥2 immunological markers. *Antigen-specific cells expressing ≥2 of the following immunological markers: CD40L, interleukin-2, tumor necrosis factor–α, or interferon-γ. Line in box, median value; top line of box, thirrd quartile; bottom line of box, first quartile; lower limit of error bar, minimum value; upper limit of error bar, maximum value; values above the bars, number of participants evaluated. Vaccination groups are as follows: 1 × H5N1-AS, single dose of the AS03A-adjuvanted vaccine; 1 × H5N1, single dose of the nonadjuvanted vaccine; 2 × H5N1-AS, double dose of the AS03A-adjuvanted vaccine; 2 × H5N1, double dose of the nonadjuvanted vaccine.

References

    1. Ferguson NM, Cummings DA, Fraser C, Cajka JC, Cooley PC, Burke DS. Strategies for mitigating an influenza pandemic. Nature. 2006;442:448–52.
    1. Germann TC, Kadau K, Longini IM, Jr., Macken CA. Mitigation strategies for pandemic influenza in the United States. Proc Natl Acad Sci USA. 2006;103:5935–40.
    1. Jennings LC, Monto AS, Chan PK, Szucs TD, Nicholson KG. Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans. Lancet Infect Dis. 2008;8:650–8.
    1. European Committee for Proprietary Medicinal Products. Committee for Medicinal Products for Human Use post-authorisation summary of positive opinion for Prepandrix (EMEA/CHMP/334055/2009). Published London, May 2009. Available at: . Accessed 1 September 2009.
    1. Leroux-Roels I, Borkowski A, Vanwolleghem T, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine. Lancet. 2007;370:580–9.
    1. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine. N Engl J Med. 2006;354:1345–51.
    1. Leroux-Roels I, Bernhard R, Gerard P, Drame M, Hanon E, Leroux-Roels G. Broad clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS One. 2008;3:e1665.
    1. Schwarz TF, Horacek T, Knuf N, et al. Single dose vaccination with AS03A-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults. Vaccine. 2009;27:6284–90.
    1. Chu DW, Hwang SJ, Lim FS, et al. Immunogenicity and tolerability of an AS03(A)-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults. Vaccine. 2009;27:7428–35.
    1. Diez-Domingo J, Garcés-Sanchez M, Baldó J-M, et al. Immunogenicity and safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase II, randomized, open, controlled study. Pediatr Infect Dis J. 2010;29 DOI:10.1097/INF.0b013e3181daf921.
    1. Rümke HC, Bayasb JM, de Juanesc JR, et al. Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. Vaccine. 2008;26:2378–88.
    1. Weinberger B, Herndler-Brandstetter D, Schwanninger A, Weiskopf D, Grubeck-Loebenstein B. Biology of immune responses to vaccines in elderly persons. Clin Infect Dis. 2008;46:1078–84.
    1. Hehme NW, Künzel W, Petschke F, et al. Ten years of experience with the trivalent split-influenza vaccine. Fluarix Clin Drug Invest. 2002;22:751–69.
    1. Stephenson I, Heath A, Major D, et al. Reproducibility of serologic assays for influenza virus A (H5N1) Emerg Infect Dis. 2009;15:252–9.
    1. Reed LJ, Muench H. A simple method of estimating fifty per cent endpoints. Am J Epidemiol. 1938;27:493–7.
    1. Maecker HT, Maino VC, Picker LJ. Immunofluorescence analysis of T-cell responses in health and disease. J Clin Immun. 2000;20:391–9.
    1. Hammarlund E, Lewis MW, Hanson SG, et al. Duration of antiviral immunity after smallpox vaccination. Nat Med. 2003;9:1131–7.
    1. Chattopadhyay PK, Yu J, Roederer M. A live-cell assay to detect antigen-specific CD4+ T cells with diverse cytokine profiles. Nat Med. 2005;11:1113–7.
    1. Frentsch M, Arbach O, Kirchoff D, et al. Direct access to CD4+T cells specific for defined antigens according to CD154 expresion. Nat Med. 2005;11:1118–24.
    1. Gioia C, Castilletti C, Tempestilli M, et al. Cross-subtype immunity against avian influenza in persons recently vaccinated for influenza. Emerg Infect Dis. 2008;14:121–8.
    1. Lee LYH, Ha DLA, Simmons C, et al. Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J Clin Invest. 2008;118:3478–90.
    1. Roti M, Yang J, Berger DA, Huston L, James EA, Kwok WK. Healthy human subjects have CD4+ T cells directed against H5N1 virus. J Immunol. 2008;180:1758–68.
    1. Corti D, Suguitan AL, Jr., Pinna D, et al. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest. 2010;120:1663–73.
    1. Rowe T, Abernathy RA, Hu-Primmer J, et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a Q1 combination of serologic assays. J Clin Microbiol. 1999;37:937–43.
    1. McElhaney JE, Xie D, Hager WD, et al. T cell responses are better correlates of vaccine protection in the elderly. J Immunol. 2006;176:6333–9.
    1. McElhaney JE, Dutz JP. Better influenza vaccines for older people: what will it take? J Infect Dis. 2008;198:632–4.
    1. McElhaney JE, Ewen C, Zhou X, et al. Granzyme B: correlates with protection and enhanced CTL response to influenza vaccination in older adults. Vaccine. 2009;27:2418–25.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren